Clinical trial Recruiting at 1 site Interventional Ages 18 to 40

Aescin (Reparil) versus Ibuprofen for pain, swelling, and limited mouth opening after impacted lower wisdom tooth removal

Official title: Evaluation of Aescin-Based Herbal Extracts for Managing Postoperative Sequelae Following Impacted Mandibular Third Molar Surgery: A Randomized, Single-Blind, Controlled Trial

Run by Oman Medical Speciality Board · NCT07244029 · Data updated 2026-11-12

We will test whether Reparil (aescin) works as well as ibuprofen to reduce pain, swelling, and jaw stiffness after impacted lower wisdom tooth removal in adults aged 18-40.

More Postoperative Pain trials

Quick facts

Study typeInterventional
Ages18 Years to 40 Years
SexAll
Enrollment100 (estimated)
SponsorOman Medical Speciality Board
Government
Locations1 site (Muscat, Al Khoud)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedOctober 20, 2026
Study endsNovember 30, 2026
Registry record updatedOctober 30, 2026
Trial IDNCT07244029 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-40 who are ASA I-II and scheduled for surgical removal of similarly positioned impacted mandibular third molars with comparable difficulty scores are ideal candidates.

Probably not a fit

Patients with contraindications to NSAIDs, known allergies to aescin or ibuprofen, pregnant or lactating women, recent use of anti-inflammatories/corticosteroids/antibiotics, or those with significant systemic disease may not benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, single-blind trial enrolling 100 adults who need surgical removal of impacted mandibular third molars at a dental center in Muscat, Oman. Participants are randomly assigned to Reparil (aescin 20 mg three times daily) or ibuprofen (400 mg three times daily) for five days after a standardized extraction. Outcomes include patient-reported pain (VAS), objective facial swelling measured with a 3D facial scanner, and mouth opening measured with a digital caliper, recorded preoperatively, on day 2, and on day 7 post-surgery. The study also monitors adverse events to compare safety profiles between the herbal extract and the NSAID.

Why it matters

Potential benefit: If successful, Reparil could provide similar pain and swelling relief to ibuprofen while reducing NSAID-related side effects.

How similar studies have gone: Aescin has shown clinical benefit for soft-tissue edema and venous disorders in other settings, but its use specifically after oral surgical extractions is novel and not extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients indicated for surgical removal of impacted mandibular third molars according to National Institute for Health and Care Excellence (NICE) guidelines.

Age between 18 and 40 years.

Impacted mandibular third molars with similar anatomical position and difficulty level as classified by Pell and Gregory and Pederson scoring.

Healthy individuals (ASA I-II) with no significant systemic illness.

Willing to provide written informed consent and attend all follow-up visits (Day 2 and Day 7 post-surgery).

Exclusion Criteria:

* Recent use (within three weeks preoperatively) of anti-inflammatories, corticosteroids, or antibiotics.

Known allergies or hypersensitivity to Aescin, Ibuprofen, rescue medications, or local anesthetics.

Pregnant or lactating women.

Patients with contraindications to NSAIDs (e.g., asthma, bleeding disorders, chronic kidney disease, active peptic ulcer, or cardiovascular disease).

Recent use of substances that may affect surgery or interact with study drugs (e.g., contraceptives, alcohol, or tobacco).

Surgical time exceeding 30 minutes or cases with intraoperative complications requiring non-study medications.

Where it's running

  • Medical City for Military and Security Services - Dental Center
    Muscat, Al Khoud, Oman
    Recruiting

Study contacts

  • Principal investigator: Suhail H AL Samari, BDS, MFD — Oman Medical Speciality Board
  • Study coordinator: Suhail H AlSamari, BDS, MFD
  • Email: suhail.dental@gmail.com
  • Phone: +968 97366511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.